Religare Investment Call

Similar documents
Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Religare Investment Call

Amber Enterprises India Ltd

DIWALI MUHURAT PICKS. October 2016

Apollo Hospitals Enterprise Ltd.

MindTree Ltd. Investment Rationale. For private circulation only. October 7 th, Volume No. I. Issue No. 43

Religare Investment Call

Larsen & Toubro Ltd.

Hinduja Global Solutions Ltd.

Goodyear India ACCUMULATE. Performance Highlights. CMP Target Price `326 `374. 1QCY2012 Result Update Tyres. Key financials

BUY. NIIT TECHNOLOGIES LTD Result Update (PARENT BASIS): Q2 FY16 SYNOPSIS. CMP Target Price OCTOBER 17 th, 2015

ITC Ltd. BUY CMP (Rs.) 304 Target (Rs.) 336 Potential Upside(%) 11% Valuation: Investment Rationale. For private circulation only

Wipro. 4QFY18 Result Update. Still not of the woods, maintain Hold. Sector: Technology CMP: ` 287. Recommendation: Hold

Mahindra & Mahindra Ltd.

Visaka Industries Ltd

Key highlights of the quarter

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

Company Overview. Industry Overview. Financial Performance

Wipro. 3QFY17 Result Update. Guidance subdued, maintain Hold. Sector: Technology CMP: ` 474. Recommendation: Hold

Music Broadcast BUY. Performance Update. CMP Target Price `293 `475. 3QFY2019 Result Update Media. Stock Info Sector Market Cap (Rs cr) Media

SQS India BFSI Ltd HOLD. Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E

Wipro. 3QFY18 Result Update. Still not of the woods, maintain Hold. Sector: Technology CMP: ` 328. Recommendation: Hold

Music Broadcast BUY. Performance Update. CMP Target Price `329 `475. 2QFY2019 Result Update Media. Historical share price chart.

Cummins India Ltd Bloomberg Code: KKC IN

Persistent Systems Ltd

KPIT CUMMINS INFOSYSTEMS Ltd.

Religare Weekly : Equity

Matrimony.com Ltd BUY. Performance Update. Target Price `1,016. 4QFY2018 Result Update Cable. Historical share price chart.

Robust results, TLT margins improved profitability.

Blue Star Ltd BUY. Performance Update. CMP Target Price `754 `867. 4QFY2018 Result Update Cons. Durable. 3-year price chart.

Company Overview. Financial Performance

HCL Technologies Ltd.

Blue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.

Tech Mahindra. Source: Company Data; PL Research

CMP* (Rs) 1,458 Upside/ (Downside) (%) 10 Bloomberg Ticker. ABB IN Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212

Maruti Suzuki India Ltd.

ACC Ltd. BUY CMP (Rs.) 1,471 Target (Rs.) 1,655 Potential Upside 13% For private circulation only. Volume No.. II Issue No. 172.

State Bank of India (SBI)

Mahindra & Mahindra Ltd.

Maruti Suzuki India BUY. Performance Update. CMP `9,315 Target Price `10,820. 1QFY2019 Result Update Automobile. Historical share price chart

IPO Product Note October 21, 2016

Tech Mahindra Ltd. RESULT UPDATE

Reliance Industries Ltd.

Fineotex Chemical Ltd

Tata Consultancy Services (TCS)

Mahindra & Mahindra Ltd.

NIIT Technologies Ltd. (NIIT Tech)

Colgate-Palmolive. Q2FY18 Result Update Volume pressure continues; Soft A&P aids Margin. Sector: FMCG CMP: ` 1,063. Recommendation: HOLD

KEI Industries BUY. Performance Update. Target Price. 3QFY2018 Result Update Cable. Historical share price chart. Key Financials

Recommendation HOLD Results in line with our expectations CMP (15/10/2010) Rs Target Rs Sector

NIIT Technologies Ltd. 15 th February, 2016 BUY

Colgate-Palmolive. Q1FY18 Result Update Volume pressure continues; Soft A&P aids Margin. Sector: FMCG CMP: ` 1,083. Recommendation: HOLD

HDFC Bank. BUY CMP (Rs.) 1,807 Target (Rs.) 2,000 Potential Upside 11%

ITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months

CMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630

Maruti Suzuki India Ltd.

TV Today Network BUY. Performance Update. CMP Target Price `315 `385. 2QFY2017 Result Update Media. Historical share price chart.

Procter & Gamble Hygiene & Health Care

KPIT Cummins ACCUMULATE. Performance Highlights CMP. `121 Target Price `132. 2QFY2013 Result Update IT. Investment Period 12 Months

NIIT Technologies. 2QFY19 Result Update. Robust revenue visibility, Outlook robust

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

Company Overview. Financial Performance

TV Today Network BUY. Performance Update CMP. `323 Target Price `498. 3QFY2019 Result Update Media. Investment Period 12 Months

NIIT Technologies. 3QFY19 Result Update. Robust revenue visibility, Outlook robust

GMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months

ICICI BANK Ltd. BUY CMP (Rs.) 334 Target (Rs.) 382 Potential Upside 15% Tide set to turn favourably... For private circulation only

Persistent Systems Ltd.

Matrimony.com Ltd BUY. A complete package from matchmaking to wedding. Target Price. Initiating Coverage Internet Software & Services

MRF BUY. Performance Highlights. CMP `9,407 Target Price `11,343. Company Update Automobile. Key financials

HDFC Bank Ltd. BUY. Investment Rationale. July 2, Volume No.. 1 Issue No. 28

Asian Granito BUY. Performance Highlights CMP. `270 Target Price `351. Outlook and valuation. 3QFY2017 Result Update Ceramics

Quick take. Ruchira Papers Ltd. BUY. Creating value through paper. Target Price. Investment Period 12 Months. 3 year daily price chart.

Tech Mahindra ACCUMLATE. Performance Highlights `495 `526. CMP Target Price. 2QFY2018 Result Update IT

Still on track. Exhibit 1: ICT is on track for FY09E

Key estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,

All the more bullish, TP upgraded

Axis Bank Ltd. For private circulation only. Volume No.. III Issue No October 08, 2018

SQS India BFSI Ltd BUY. World s Leading Specialist in Financial Services Testing. Valuation and Outlook. Key Risks

Nestlé India Outlook Hazy; Valuations Prohibitive

CCL Products BUY. Brewing Steadily. CMP Target Price `300 `360. Initiating Coverage Coffee. January 4, year price chart

Tata Consultancy Services (TCS)

Nestle India Ltd. RESULT UPDATE

Bloomberg Code: ATA IN

Hindustan Media Ventures

BUY CMP (Rs.) 297 Target (Rs.) 385 Potential Upside 30%

Bharat Forge. Result Update. Q4FY13 Result Highlights. Valuation. No Respite in Sight May 29, Institutional Research 1

Sanghvi Movers Ltd. Results above estimates. Figure 1: Actual Vs Religare Estimates. Financial highlights. Valuations and Recommendation

Transcription:

CMP (Rs) Target Price (Rs) Potential Upside Sensex Nifty Key Stock data BSE Code NSE Code Bloomberg Shares o/s, Cr (FV 1) Market Cap (Rs Cr) 1 Year Avg Volume 52 week H/L Shareholding Pattern (%) Promoter FII DII Others 1 Year price performance 15 125. 1 75. Sep-15 Analyst Nov-15 Dec-15 Dec-15 51.5 1.3 47. Feb-16 Cigni Mar-16 Archana Gude archana.gude@religare.com +91-22 - 6728853 419 538 28.3% 28,334 8,769 534758 CIGNITITEC CIGN:IN 2.5 1,63 38,191 517/369 Mar-16 Jun -16 51.4.1 48.3 May-16 Ni y Jun-16 51.3.1 48.5 Aug-16 Sep-16 is the second largest Independent Quality Testing provider with its 2,2+ headcount in the world. The company has emerged as pure play software testing provider and offers a variety of testing services to diverse industry vertical across geographies. Cigniti operates from US, UK, Australia, Canada and its global delivery centre is at Hyderabad, India. The company has over 2+ active clients comprising enterprises as well as independent software vendors. We believe the company is well placed to benefit from growth of quality testing services industry, which is growing at CAGR of 7%, higher than IT industry growth rate. Investment rationale Cigniti is the world's first CMMI-SVCv1.3, Maturity Level 5 certified Independent Software Testing Services (STS) company. The company's IP led offerings include Quality Assurance, Quality Engineering, Digital Assurance and Advisory & Transformation services. Cigniti's SMART Tools and testing labs in Enterprise Mobility, cloud enabled performance engineering, Robotics, IoT & Smart meters differentiates it from its peers. Considering Cigniti's experience of working with Fortune 5 companies and its expertise in quality testing services, we believe, it is well placed to capture incremental quality testing industry revenue pie. The company has strong 2+ active clients base across BFSI, Healthcare, Travel and Hospitality, Energy and Utilities, Media and e-commerce. Cigniti's revenue contribution from the clients is well spread and the deals are multi-year in nature. In FY216, 46% of the revenue was from top 2 clients while over 47 clients were under Rs 2cr and above deal size. Cigniti's profound expertise, timely execution skills and ability to handle cross verticle, cross functional deals will support growth momentum in future. Globally specialised software testing industry is estimated to grow at a CAGR of ~7% over CY15-2 to reach USD 25.9bn. Growth in STS spends is higher than total IT spends, depicting huge growth opportunity for specialised testers like Cigniti. Also, the company is looking at a small/mid-sized inorganic acquisition in Europe, which if happens will give access to growing EMEA region to the company and will aid in higher revenue growth. Outlook and Valuation, the second largest independent quality testing company in the world by headcount, has 2+ active clients across Latin America, Europe, India and rest of the world. Cigniti's expertise in quality testing across verticals and the company's SMART Tools and test labs differentiates it with its peers. We estimate Revenue, Ebitda and PAT to grow at a CAGR 25.3%, 26.3% and 31.3% respectively over FY16-18E. The stock is trading at 12.5x PE @ FY18E. We recommend BUY on the stock with a price target of Rs 538. Financial Summary Particulars, Rs Cr Net sales EBITDA EBITAM (%) PAT PATM (%) EPS, Rs PE, (x) RoE (%) 259.1 35.6 13.7% 25.6 9.9% 12.3 34.1 31.2 379.3 38.5 1.1% 25.4 6.7% 1.4.3 13.6 594.9 98.1 16.5% 49.7 8.4% 19.5 21.5 15.8 748.7 121.2 16.2% 64.9 8.7% 25.5 16.5 16.6 933.4 156.5 16.8% 85.7 9.2% 33.6 12.5 18.3 October 5, 216

Investment Rationale Software testing - Fastest growing amongst IT services Total testing spends to grow at a CAGR of 2.3% over CY15-2 Software testing accounts for 6% of total IT spending. Total testing industry is estimated to reach USD 42.8bn in CY22 from USD 38.2bn in CY215, growing at a CAGR 2.3% over CY15-2E. Interestingly, total IT spends and spends on software testing are growing at same level, though latter was not considered as crucial spends globally in the past. IT Spend by category 6% IT Services spending 94% Tes ng spending Total Testing Industry size (USD bn) 44 43 42 41 39 38 37 36 35 38.2 39.1 39.9.7 41.7 42.8 CY15 CY16E CY17E CY18E CY19E CY2E Total Tes ng spending Source : Nelson Hall IT Industry Report Software Testing is divided into traditional software testing (TST) and specialised software testing (SST). Earlier, IT service providers used to do in - house software testing, which is known as traditional software testing. However, with complexity of business environment, enterprises are now focused on third party certification for reliability and accuracy of software, which is also known as specialised software testing. In CY212, Specialised testing contributed only 3% of total testing spends. However, with increase in demand for specialised testing globally, shift of spends from traditional testing to specialised testing is imminent. As per Nelson Hall's report, Specialised Testing will contribute 71% of total testing spends at USD 25.9bn. Though software testing is expected to grow at a CAGR of 2% over CY15-2E, Specialised software testing is estimated to grow at a CAGR of 7% during the same period. Shift from Traditional testing to Specialised testing STS Spending growing steadily Share of STS spending to increase to 71% in CY2 12% 1% 8% 6% % 2% % 3% 7% CY12 71% 39% CY2E (USD bn) (%) 3 9.% 8.% 7.5% 6.6% 27 7.% 6.5% 6.6% 8.% 24 7.% 21 6.% 18 5.% 15 4.% 12 9 3.% 6 2.% 3 1.% 18.6 2 21.4 22.8 24.3 25.9 % CY15 CY16E CY17E CY18E CY19E CY2E Tradi onal Tes ng Specialised Tes ng STS Spending, USD bn YoY Growth Source : Nelson Hall IT Industry Report

Well placed to capture increasing spends across the industry verticals As per Nelson Hall's report, in CY15, BFSI, telecom and media contributed over 5% of total testing spends. Another 25% is contribued by manufacturing and retail companies. Rest of the testing spends pie is occupied by healthcare, energy & utilities, transportation, etc. In FY16, Cigniti's 18% revenue came from BFSI sector while 19% was contributed by travel and hospitality. Considering Cigniti's expertise to work with Fortune 5 companies, we believe the company has major scope to grow and capture higher pie of testing spends. Also, retail and consumer product goods, booming sectors in India and across the globe, were just 2% of total Cigniti's sales in FY16. We believe, Cigniti is well placed to get higher revenue from these verticals. Testing spending breakdown by sector (CY15) Cigniti - Revenue contribution by sector (FY16) 18% 2% 4% 3% 5% 38% 17% 2% 3% 35% 6% 5% 1% 16% Financials Telecom & Media Retail CPG Healthcare Manufacturing Transporta on Energy & U li es Government Others 19% Independent So ware Vendors Travel and Hospitality Energy and U li es Others 18% BFSI Healthcare Retail & E-Commerce Strong clientele base to support growth projection Working with 2+ active clients Cigniti has worked with over 5 clients since inception and has currently 2+ active clients. The company s strategic decision of not to depend on a few clients for revenue has paid off well. In FY16, top client accounted for 15% of total sales of the company while top 2 clients contributed 46% of total sales. In terms of deal size, the company has focused approach towards size and tenure of the deals. Company's 47 project deals were above Rs 2crs while 167 deals were from Rs.1cr -.5cr size. This strategy will not only act as a cushion in case of loss of a client but also helps to get clients with small testing spends initially. Revenue contribution - As per clients Revenue contribution - As per dealsize 5% 45% % 35% 3% 25% 2% 15% 1% 5% % 46% 35% 26% 15% Top client Top 5 Top 1 Top 2 (Rs cr) 18 16 1 12 1 8 6 2 167 83 83 61 47 2Crs + 1Cr - 2Cr.5Cr - 1Cr.1Cr -.5Cr Less than.1cr

Organic growth continues; Inorganic expansion on cards Inorganic expansion will aid revenue growth Cigniti's focused approach towards increasing footprints in Europe and India has helped in reducing revenue share from North America in total sales from 91% in FY15 to 86% in FY16. Europe and India had a share of 5% each in total sales. The company is also looking at a small/mid - sized company acquisition in Europe to get easier access to testing markets in UK/Europe and increase visibility. EMEA is estimated to have % share in total STS spends of USD 25.9bn. Inorganic expansion will give access to growing EMEA region and aid revenue growth. Total STS Spending - by region CY2E Revenue contribution - by region FY16 1% 3% 5% 4% 5% 47% % 86% North America EMEA APAC La n America North America Europe India Rest of the World

Financial Analysis Net sales & YoY growth EBITDA & EBITDAM (Rs cr) (%) (Rs cr) 1 9 8 7 6 5 3 2 1 1 9 8 71.7 57. 7 46.2 6 5 3 25.9 24.7 2 1 259.1 379.3 594.9 748.7 Net sales yoy Growth (%) 933.4 18 16 1 12 1 8 6 2 16.8 13.7 16.2 16.5 1.2 35.6 38.5 98.1 121.2 156.5 EBITDA EBITAM (%) (%) 18 16 14 12 1 8 6 4 2 PAT & PATM Cash Flow (Rs cr) (%) (Rs cr) 9 8 7 6 5 3 2 1 9.9 8.4 8.7 9.2 6.8 25.6 25.4 49.7 64.9 85.7 16 14 12 1 8 6 4 2 25 2 15 1 5-5 -1-15 -2-25 Cashflow from Opera ng ac vi es Cashflow from Inves ng ac vi es PAT PATM (%) Cashflow from Financing ac vi es RoE & RoCE Working Capital Cycle (%) 35 32.4 1 3 25 2 15 1 5 31.2 23.4 21.5 23.9 15.3 18.3 15.8 16.6 13.6 12 1 8 6 2 13 9 18 95 9 46 49 35 18 RoE RoCE Debtors days Creditors days

Company background, formerly known as Chakkilam Infotech Ltd., was incorporated in 1998. In September 211, the company acquired Cigniti Inc. and changed the name to The company is focused on software testing services through a combination of onsite consulting and offshore delivery. Ciginiti has 2,2+ career testers servicing over 2+ clients across 5 continents. Its offices are in US, UK, India, Canada and Australia. Cigniti is the first company to be rated as CMMI-SVC v1.3 Maturity Level 5. The company's IP led offerings include Quality Assurance, Quality Engineering, Digital Assurance and Advisory & Transformation services. Cigniti's SMART Tools and testing labs in Enterprise Mobility, cloud enabled performance engineering, Robotics, IoT & Smart meters differentiates it amongst its peers. In 216, the company's Cigniti 4. Quality Engineering strategy that focuses on Digital assurance for the new age enterprises backed by patented IP led approach, investments into cutting-edge cloud-enabled test labs, and impeccable focus to accelerate the market readiness of its clients' software through best in class testing services has resulted in better positing amongst the peers. Key Clients across business verticals BFSI Energy & Utility HCLS Strong clientele base across industry vertical Travel & Hospitality Media & Technology Retail & E-Commerce

Board of directors Name C V Subrahmanyam Sudhakar Pennam C Srikanth K Ch. Subba Rao Mani Subramanian K Nageswara Rao K Krishna Priya Designation Chairman & Managing Director Director Executive Director Independent Director Independent Director Independent Director Independent Director Key Risks: Slower pace of IT spending growth is expected due to economic weakness in emerging markets. As per NASSCOM IT Industry report, global IT spends grew by 5 6% in constant currency terms since recovery from the financial crisis in 21. However, IT market is now expected to grow by just 2% in CY16. Cut down in IT spends will impact negatively to Quality Testing companies as well. Software quality testing is fragmented between traditional testing companies and specialised testing companies. Top 15 IT companies in the world had 73% share in total spend on quality testing in CY15 while remaining 27% was contributed by independent software companies like Cigniti. Increase in competitive intensity will weigh on earnings for software testing companies.

P&L Account - Consolidated Particulars, Rs Cr Net sales 259.1 378.9 594.8 748.7 933.4 Increase/(Decrease) in stock.4.1 Total income 259.1 379.3 594.9 748.7 933.4 Expenditure Employee cost 173.2 223.6 38.7 382.8 478.5 Other expenses 5.3 117.3 188.1 244.6 298.4 Total expenditure 223.5 3.8 496.9 627.4 776.9 EBITDA 35.6 38.5 98.1 121.2 156.5 Other income.9 1.2 3.3 5.8 8.7 Depreciation 2.4 5.4 11.3 19.4 22.9 PBIT 34.1 34.2 9.1 17.7 142.3 Interest expenses 1.2 2.9 6. 7.8 1.5 PBT 32.9 31.3 84.1 99.9 131.8 Tax 7.3 5.5 34.4 35. 46.1 PAT 25.6 25.7 49.7 64.9 85.7 Source : Company ; RSL Research Balance sheet - Consolidated Particulars, Rs Cr Share Capital 2.8 24.7 25.5 25.5 25.5 Reserves & Surplus 87.4 244.3 334.1 399. 484.7 Total Shareholder's Fund 18.2 269.1 359.6 424.5 51.2 Share application money pending 4.2 Long term borrowings.2 3.6 Trade payables 12.9 36. 64.6 94.6 124.6 Short term Borrowings 25.2 38.3 96.6 111.6 131.6 Other current liabilities 34.2 37.1 115.2 137. 169.8 Total liabilities 184.9 384.1 635.9 767.6 936.1 Net Block 78.6 126.2 25.7 226.3 253.5 Other non current assets 19.1 16.3 148.9 163.8 182.4 Sundry Debtors 63.9 134.7 175.8 194.9 23.2 Cash & Cash equivalents 5.7 33.9 4.2 71.2 136.4 Other current assets 17.8 73. 11.3 111.4 133.7 Total assets 184.9 384.1 635.9 767.6 936.1 Source : Company ; RSL Research

Cash Flow - Consolidated Particulars, Rs Cr Net profit before tax & extraordinary items 24.5-28.1 84. 99.9 15.7 Operating profit before working capital changes 34.2 65. 141.5 127. 165.2 Cash geenrated from/(used in) operations 24.5-28.1 182.7 132. 148.1 Cash flow from operations 24.5-28.1 182.7 99.9 15.7 Cash flow from Investing activities -53.4-51.2-23.5-4 -5 Cash flow from Financing activities 32.5 17.5-8.9 7.2 9.5 Net Inc/(Dec) Cash & Cash equivalents 3.7 28.2-29.7 67.1 65.2 Cash & Cash equivalents at the beginning of the year 2. 5.7 33.9 4.2 71.2 Cash & Cash equivalents at the end of the year 5.7 33.9 4.2 71.2 136.4 Source : Company ; RSL Research Key Financial ratios Particulars Profitability Ratios Gross Profit/ Net sales (%) 33.8 27.6 32. 31.5 32.1 EBITDA / Net Sales (%) 13.7 1.2 16.5 16.2 16.8 NPM / Total income (%) 9.9 6.8 8.4 8.7 9.2 ROE (%) 31.2 13.6 15.8 16.6 18.3 ROCE (%) 32.4 15.3 23.4 21.5 23.9 Turnover Days Debtors Velocity 9 13 18 95 9 Creditors Velocity 18 35 46 49 Gross Asset Ratio 3.6 3.2 3.1 2.9 3.1 Liquidity Ratios Gross Debt-Equity Ratio.2.2.3.3.3 Interest Coverage 27.9 11.2 14.4 13. 12.7 Current Ratio (x) 1.2 2.2 1. 1.1 1.2 Source : Company ; RSL Research

Before you use this research report, please ensure to go through thedisclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 214 and Research Disclaimer at the following link : http://old.religareonline.com/research/disclaimer/disclaimer_rsl.html Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 214 is/are as under: Statements on ownership and material conflicts of interest, compensation Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) below, are given separately] S. No. Statement Answer Tick appropriate YES I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interestis given below this table] I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance? I / we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance? I/we have received any compensation from the subject company in the past twelve months? I/we have managed or co-managed public offering of securities for the subject company in the past twelve months? I/we have received any compensation for brokerage services from the subject company in the past twelve months? I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months? I/we have received any compensation or other benefits from the subject company or third party in connection with the research report? I/we have served as an officer, director or employee of the subject company? I/we have been engaged in market making activity for the subject company? Nature of Interest ( if answer to F (a) aboveis Yes :... Name(s)with Signature(s)of RA(s). [Please note that only in case of multiple RAs andif the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) above, are given below] SS.No Name(s) of RA Signatures of RA Serial Question of question which the signing RA needs to make separate declaration / answer YES Copyright in this document vests exclusively with RSL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RSL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person. Disclaimer: www.religareonline.com/research/disclaimer/disclaimer_rsl.html